Actually, approval of blarcamesine for Alzheimer’s anywhere in the world will lead to global availability.
If Anavex gets Alzheimer’s approval of blarcamesine in Aussieland, patients there will start to improve. Their therapeutic successes won’t be a secret. The drug will be safe (no side effects of any consequence), will be easily taken (an oral pill or two each day; no infusions at a medical facility), and favorable therapeutic responses will be quickly noted; including enhanced health-giving sleep patterns.
With reports of all of that in Australia — or anywhere else — there will be strong popular, even political pressures to make the drug available in countries across the globe.
They are going for the FDA approval based on the fact that the FDA will be changing the rules for submitting an NDA. Why would you want to waste your time, money and resources on Australia when you have much larger fish to fry. Go EMA and go FDA.